Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
McKinsey
Express Scripts
Harvard Business School
Johnson and Johnson

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Fresolimumab

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Fresolimumab?

Fresolimumab is an investigational drug.

There have been 5 clinical trials for Fresolimumab. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2011.

The most common disease conditions in clinical trials are Glomerulosclerosis, Focal Segmental, Brain Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Genzyme, a Sanofi Company, University of California, Los Angeles, and Hospital for Special Surgery, New York.

There are five US patents protecting this investigational drug and forty-five international patents.

Recent Clinical Trials for Fresolimumab
TitleSponsorPhase
Safety of Fresolimumab in the Treatment of Osteogenesis ImperfectaGenzyme, a Sanofi CompanyPhase 1
Safety of Fresolimumab in the Treatment of Osteogenesis ImperfectaHospital for Special Surgery, New YorkPhase 1
Safety of Fresolimumab in the Treatment of Osteogenesis ImperfectaHugo W. Moser Research Institute at Kennedy Krieger, Inc.Phase 1

See all Fresolimumab clinical trials

Clinical Trial Summary for Fresolimumab

Top disease conditions for Fresolimumab
Top clinical trial sponsors for Fresolimumab

See all Fresolimumab clinical trials

US Patents for Fresolimumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fresolimumab   Start Trial Determination of TGF-.beta. pathway activity using unique combination of target genes KONINKLIJKE PHILIPS N.V. (Eindhoven, NL)   Start Trial
Fresolimumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Fresolimumab   Start Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY)   Start Trial
Fresolimumab   Start Trial Imaging composition and uses thereof The University of Melbourne (Melbourne, AU)   Start Trial
Fresolimumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fresolimumab

Drugname Country Document Number Estimated Expiration Related US Patent
Fresolimumab Australia 2015334840 2034-10-24   Start Trial
Fresolimumab Brazil 112017007965 2034-10-24   Start Trial
Fresolimumab Canada 2965442 2034-10-24   Start Trial
Fresolimumab China 107077536 2034-10-24   Start Trial
Fresolimumab European Patent Office 3210142 2034-10-24   Start Trial
Fresolimumab Japan 2018503354 2034-10-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Moodys
Medtronic
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.